EP0789021B1 - Hydroxamsäuren als Kappa-Opiat-Rezeptoragonisten - Google Patents
Hydroxamsäuren als Kappa-Opiat-Rezeptoragonisten Download PDFInfo
- Publication number
- EP0789021B1 EP0789021B1 EP97200003A EP97200003A EP0789021B1 EP 0789021 B1 EP0789021 B1 EP 0789021B1 EP 97200003 A EP97200003 A EP 97200003A EP 97200003 A EP97200003 A EP 97200003A EP 0789021 B1 EP0789021 B1 EP 0789021B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxy
- alkyl
- phenyl
- dichlorophenyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- opioid analgesics such as morphine act as a ⁇ -receptor agonist
- separating the action based on a ⁇ -receptor agonist from the action based on ⁇ -receptor agonist has been investigated.
- the present invention provides a compound of the following formula: or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 2-4 alkenyl, C 1-4 alkoxy-C 1-4 alkyl, C 1-4 alkylthio-C 1-4 alkyl, halo-substituted C 1-4 alkyl or hydroxy-C 1-4 alkyl or R 1 and R 2 are taken together with the nitrogen to which they are attached and form a saturated or unsaturated 3-, 4-, 5-, 6- or 7- membered heterocyclic containing one to two heteroatoms, optionally substituted with C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, halo (i.e., fluoro, chloro, bromo or iodo), benzyl, hydroxy, carboxy, cyano, nitro, di C 1-6 alkylamino, amino, C 1-6 alkylsu
- X is phenyl substituted with up to three substituents selected from chloro, methyl and CF 3, preferably 3,4-dichlorophenyl; and R 3 is hydrogen.
- Preferred individual compounds of the invention are:
- the ⁇ agonists compounds of formula (I) of this invention can be administered via either the oral, parenteral or topical routes to mammals.
- these compounds are most desirably administered to humans in doses ranging from 0.01 mg to 50 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated, the disease state being treated and the particular route of administration chosen.
- a dosage level that is in the range of from 0.01 mg to 1 mg per kg of body weight per day, single or divided dosage is most desirably employed in humans for the treatment of pain in a postoperative patient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Claims (11)
- Verbindung der nachstehenden Formel oder ein pharmazeutisch verträgliches Salz davon, worinR1 und R2 unabhängig voneinander Wasserstoff, C1-4-Alkyl, C3-7-Cycloalkyl, C2-4-Alkenyl, C1-4-Alkoxy-C1-4-alkyl, C1-4-Alkylthio-C2-4-alkyl, Halogen-substituiertes C1-4-Alkyl oder Hydroxy-C1-4-alkyl darstellen; oder R1 und R2 mit dem Stickstoffatom, an das sie gebunden sind, zusammengenommen einen ein bis zwei Heteroatome enthaltenden, gesättigten oder ungesättigten 3-, 4-, 5-, 6- oder 7-gliedrigen Heterocyclus bilden, der gegebenenfalls mit C1-6-Alkyl, C1-6-Alkoxy, C2-6-Alkenyl, Halogen (das heißt Fluor, Chlor, Brom oder Jod), Benzyl, Hydroxy, Carboxy, Cyano, Nitro, Di-C1-6-alkylamino, Amino, C1-6-Alkylsulfonylamino, Mercapto, C1-6-Alkylthio, C1-6-Alkylsulfinyl, C1-6-Alkylsulfonyl, Phenyl, Phenoxy und OY, worin Y eine Hydroxyschutzgruppe darstellt, substituiert ist, mit der Maßgabe, dass der Heterocyclus nicht Pyrrolidinyl ist;R3 Wasserstoff, C1-4-Alkyl oder eine Hydroxyschutzgruppe darstellt;Ar Phenyl, gegebenenfalls substituiert mit ein oder mehreren Substituenten, unabhängig ausgewählt aus Halogen, Hydroxy, C1-4-Alkyl, C1-4-Alkoxy, C1-4-Alkoxy-C1-4-alkyloxy, CF3 und Carboxy-C1-4-alkyloxy, darstellt; undX Phenyl, Naphthyl, Biphenyl, Indanyl, Benzofuranyl, Benzothiophenyl, 1-Tetralon-6-yl, C1-4-Alkylendioxy, Pyridyl, Furyl oder Thienyl darstellt, wobei diese Gruppen gegebenenfalls mit bis zu drei Substituenten, ausgewählt aus Halogen, C1-4-Alkyl, C1-4-Alkoxy, Hydroxy, NO2, CF3 und SO2CH3, substituiert sind.
- Verbindung nach Anspruch 1, worin R1 und R2 unabhängig voneinander C1-4-Alkyl oder Halogen-substituiertes C1-4-Alkyl darstellen; oder R1 und R2 zusammengenommen eine 5- oder 6-gliedrige cyclische Aminogruppe bilden, die gegebenenfalls mit ein bis drei Substituenten, ausgewählt aus Hydroxy, Halogen, C1-4-Alkyl oder -OY, worin Y eine Hydroxyschutzgruppe darstellt, substituiert sind.
- Verbindung nach Anspruch 2, worin Ar Phenyl darstellt.
- Verbindung nach Anspruch 3, worin X Phenyl, substituiert mit bis zu drei Substituenten, ausgewählt aus Chlor, Methyl und CF3, darstellt und R3 Wasserstoff darstellt.
- Verbindung nach Anspruch 4, worin X 3,4-Dichlorphenyl darstellt.
- Verbindung nach Anspruch 1, die eine der nachstehenden ist:2-(3,4-Dichlorphenyl)-N-hydroxy-N-(1-(S)-phenyl-2-piperidinoethyl)acetamid;2-(3,4-Dichlorphenyl) -N-hydroxy-N-[1-(S)-phenyl-2-(3-pyrrolidinoethyl)]acetamid;2-(3,4-Dichlorphenyl)-N-hydroxy-N-[1-(S)-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)ethyl]acetamid;2- (3,4-Dichlorphenyl)-N-(2-N,N-dimethylamino-1-(S)-phenylethyl)-N-hydroxyacecamid;N-(2-Azetidinyl-1-(S)-phenylethyl)-N-hydroxy-2-(3,4-dichlorphenyl)acetamid;2-(3,4-Dichlorphenyl)-N-(2-hexamethylenimino-1-(S)-phenylethyl) -N-hydroxyacetamid;2-(2,3-Dichlorphenyl)-N-hydroxy-N-[1-(S)-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)ethyl]acetamid;N-Hydroxy-N-[1-(S)-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)ethyl]-2-(2,3,6-trichlorphenyl)acetamid; und2-(3,4-Dichlorphenyl)-N-[2-N'-(2-fluorethyl)-N'-methylamino-1-(S)-phenylethyl)-N-hydroxyacetamid.
- Verbindung nach Anspruch 1, die eine der nachstehenden ist:2-(3,4-Dichlorphenyl)-N-hydroxy-N-(1-(S)-phenyl-2-piperidinoethyl)acetamid;2-(3,4-Dichlorphenyl)-N-hydroxy-N-[1-(S)-phenyl-2-(3-pyrrolidinoethyl)]acetamid;2-(3,4-Dichlorphenyl)-N-hydroxy-N-[1-(S)-phenyl-2-(1,2,3,6-tetrahydropyridin-1-yl)ethyl]acetamid; und2- (3,4-Dichlorphenyl) -N- [2-N'- (2-fluorethyl) -N'-methylamino-1-(S)-phenylethyl]-N-hydroxyacetamid.
- Pharmazeutische Zusammensetzung, umfassend eine Verbindung der Formel (I) oder ein pharmazeutisch verträgliches Salz davon nach einem der Ansprüche 1 bis 7, zusammen mit einem pharmazeutisch verträglichen Verdünnungsmittel oder Träger.
- Verbindung der Formel (I) oder ein pharmazeutisch verträgliches Salz davon nach einem der Ansprüche 1 bis 7 oder eine pharmazeutische Zusammensetzung, die eine solche Einheit enthält, nach Anspruch 8, zur Verwendung als Arzneimittel.
- Verwendung einer Verbindung der Formel (I) oder eines pharmazeutisch verträglichen Salzes davon nach einem der Ansprüche 1 bis 7, zur Herstellung eines Arzneimittels zur Behandlung eines Zustands, für den Agonistenaktivität gegen einen opfolden Kapparezeptor benötigt wird.
- Verwendung einer Verbindung der Formel (I) oder eines pharmazeutisch verträglichen Salzes davon nach einem der Ansprüche 1 bis 7, zur Herstellung eines Arzneimittels, das als analgetisches, antientzündliches, diuretisches, hustenlinderndes, anästhetisches oder neuroprotektives Mittel wirksam ist oder für die Behandlung von Schlaganfall oder funktioneller Darmerkrankung.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT97200003T PT789021E (pt) | 1997-01-07 | 1997-01-07 | Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB9600099 | 1996-02-07 | ||
WOPCT/IB96/00099 | 1996-02-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0789021A1 EP0789021A1 (de) | 1997-08-13 |
EP0789021B1 true EP0789021B1 (de) | 2000-10-11 |
Family
ID=11004404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97200003A Expired - Lifetime EP0789021B1 (de) | 1996-02-07 | 1997-01-07 | Hydroxamsäuren als Kappa-Opiat-Rezeptoragonisten |
Country Status (10)
Country | Link |
---|---|
US (1) | US5837717A (de) |
EP (1) | EP0789021B1 (de) |
JP (1) | JP3190588B2 (de) |
AT (1) | ATE196901T1 (de) |
CA (1) | CA2196845C (de) |
DE (1) | DE69703256T2 (de) |
DK (1) | DK0789021T3 (de) |
ES (1) | ES2151222T3 (de) |
GR (1) | GR3034923T3 (de) |
MX (1) | MX9701042A (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982297A3 (de) * | 1998-08-24 | 2001-08-01 | Pfizer Products Inc. | Verfahren zur Herstellung von Hydroxy-pyrrolidinyl Hydroxamsäure Derivaten, die kappa Opioid-Rezeptor Agonisten sind |
US7160902B2 (en) | 2003-11-14 | 2007-01-09 | Adolor Corporation | Amide derivatives and methods of their use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618188D0 (en) * | 1986-07-25 | 1986-09-03 | Ici Plc | Diamine compounds |
US5232978A (en) * | 1988-12-23 | 1993-08-03 | Merck Patent Gesellschaft Mit Beschrankter Haftung | 1-(2-arylethyl)-pyrrolidines |
DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
JPH0730061B2 (ja) * | 1991-02-07 | 1995-04-05 | ファイザー製薬株式会社 | ヒドロキサム酸誘導体および組成物 |
US5132319A (en) * | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
US5128364A (en) * | 1991-03-28 | 1992-07-07 | Merck Frosst Canada, Inc. | Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis |
US5234933A (en) * | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
IL117440A0 (en) * | 1995-03-31 | 1996-07-23 | Pfizer | Pyrrolidinyl hydroxamic acid compounds and their production process |
-
1996
- 1996-02-07 MX MX9701042A patent/MX9701042A/es unknown
-
1997
- 1997-01-07 AT AT97200003T patent/ATE196901T1/de not_active IP Right Cessation
- 1997-01-07 DE DE69703256T patent/DE69703256T2/de not_active Expired - Fee Related
- 1997-01-07 EP EP97200003A patent/EP0789021B1/de not_active Expired - Lifetime
- 1997-01-07 ES ES97200003T patent/ES2151222T3/es not_active Expired - Lifetime
- 1997-01-07 DK DK97200003T patent/DK0789021T3/da active
- 1997-01-28 US US08/790,246 patent/US5837717A/en not_active Expired - Fee Related
- 1997-02-05 CA CA002196845A patent/CA2196845C/en not_active Expired - Fee Related
- 1997-02-06 JP JP03692597A patent/JP3190588B2/ja not_active Expired - Fee Related
-
2000
- 2000-11-28 GR GR20000402630T patent/GR3034923T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE196901T1 (de) | 2000-10-15 |
DK0789021T3 (da) | 2000-11-13 |
CA2196845C (en) | 2001-08-21 |
CA2196845A1 (en) | 1997-08-08 |
US5837717A (en) | 1998-11-17 |
DE69703256T2 (de) | 2001-02-22 |
JPH11180950A (ja) | 1999-07-06 |
JP3190588B2 (ja) | 2001-07-23 |
EP0789021A1 (de) | 1997-08-13 |
DE69703256D1 (de) | 2000-11-16 |
ES2151222T3 (es) | 2000-12-16 |
MX9701042A (es) | 1998-05-31 |
GR3034923T3 (en) | 2001-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2351588C2 (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии | |
RU2125041C1 (ru) | Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения | |
AU5714096A (en) | Substituted oximes, hydrazones and olefins as neurokinin antagonists | |
EP0783490A1 (de) | 1-acyl-4-aliphatische aminopiperidin verbindungen | |
WO1993016048A1 (en) | Substituted acetamide compound | |
AP625A (en) | Pyrrolidinyl hydroxamic acid compounds and their production process. | |
US5837720A (en) | N-2-(pyrrolidinyl-1)-1-phenethyl) acetamides as kappa receptor antagonists | |
KR970008313B1 (ko) | 4-페닐-4-[n-(페닐)아미도]피페리딘 유도체, 제약학적 조성물 및 이런 화합물을 이용하는 방법 | |
EP0789021B1 (de) | Hydroxamsäuren als Kappa-Opiat-Rezeptoragonisten | |
US5138062A (en) | Nicotine analogs | |
JP3233276B2 (ja) | カッパアゴニストとしてのヒドラジド化合物 | |
KR19990071965A (ko) | 5-나프탈렌-1-일-1,3-디옥산 유도체, 그 제조방법 및 치료학적사용 | |
US6624313B2 (en) | Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists | |
AU645685B2 (en) | New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them | |
PT789021E (pt) | Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao | |
MXPA00010456A (es) | Agentes serotonergicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970107 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990420 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19990420 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 196901 Country of ref document: AT Date of ref document: 20001015 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REF | Corresponds to: |
Ref document number: 69703256 Country of ref document: DE Date of ref document: 20001116 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2151222 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20001110 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20041210 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20041213 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20041215 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20041220 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20041229 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FI Payment date: 20050103 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050107 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20050107 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20050118 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20050127 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20050317 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051209 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20060104 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060107 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060107 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060108 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20060123 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20060125 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20060131 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060707 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060801 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Effective date: 20060707 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20060801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070801 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20070107 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070107 |
|
BERE | Be: lapsed |
Owner name: *PFIZER INC. Effective date: 20060131 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20070108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060802 |